Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are comparing how long adults with moderate to severe active rheumatoid arthritis RA continue treatment with Upadacitinib UPA versus tumor necrosis factor inhibitors TNFi under real-world conditions in Germany. This observational study includes about 678 participants across approximately 80 sites and aims to understand treatment persistence over time. Participants will receive either Upadacitinib or a TNFi as prescribed by their doctors according to local labels and standard care practices. The choice of treatment is made independently of the study, and the study does not assign treatments but observes patients receiving these therapies in routine care. During the study, participants will be followed for up to 24 months to monitor how long they continue their prescribed treatment. Researchers will collect data on treatment retention rates and other health information during this period. The total study duration, including recruitment and follow-up, is about 48 months.
Actively Recruiting
Researchers are evaluating real-world clinical and patient-reported outcomes in adults with systemic lupus erythematosus SLE who are starting subcutaneous anifrolumab treatment for the first time. This prospective, single-arm, multicenter non-interventional study aims to describe key treatment goals such as remission DORIS and low disease activity LLDAS, quality of life, medication patterns, flares, and organ damage in routine care. Participants will be observed over a 24-month period while receiving subcutaneous anifrolumab as prescribed in routine clinical practice, following the applicable European summary of product characteristics. The study does not intervene in treatment decisions but collects information on disease activity, medication use, and clinical outcomes during this time. During the 24 months, data will be collected from routine visits including assessments of disease activity indices, patient questionnaires on fatigue and quality of life, and monitoring of flares and organ damage. Researchers will measure outcomes such as the proportion of patients achieving remission at 24 months and changes in disease activity scores, aiming to capture long-term disease control and treatment patterns.
Actively Recruiting
Researchers are conducting a prospective registry study to observe and document the treatment and disease progression in patients with recurrent and metastatic prostate cancer. The study includes four distinct patient groups based on disease status those with biochemical recurrence after local treatment, non-metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, and metastatic castration-resistant prostate cancer. Each group is enrolled and followed independently over different time periods to understand the course of therapy and disease. The study does not prescribe any specific treatment but records routine care as decided by each patients physician. Data collection occurs during routine clinical visits at set intervals, including after enrollment, every 3 to 6 months, and when therapy changes occur. Standardized quality of life questionnaires FACT-P and EQ-5D-5L are completed, and biological samples are collected to support comprehensive assessment. Participants are followed long-term, with an average follow-up of seven years. Researchers document therapy patterns, disease management strategies, imaging assessments, patient-reported outcomes, treatment adherence, and adverse events throughout this period. The focus is on real-world data reflecting everyday clinical practice, enabling a detailed understanding of treatment effectiveness and disease progression in prostate cancer patients.
Actively Recruiting
Researchers are observing participants with Chronic Lymphocytic Leukemia CLL who are receiving venetoclax either alone or combined with rituximab, obinutuzumab, ibrutinib, or acalabrutinib. The study aims to assess the effectiveness, health-related costs, and participant-reported outcomes in real-life clinical settings, reflecting typical medical practice. This observational study is sponsored by AbbVie and involves patients treated according to local clinical guidelines. Participants are grouped based on their treatment regimen, including venetoclax alone or with one of the specified combination therapies. Treatments are prescribed at the physicians discretion and according to local labels, without experimental intervention from the study. The study captures data as patients receive their usual care with these therapies. During the study, participants responses to treatment are monitored, focusing on the best overall response rate within 12 months. Researchers collect health economic data and patient-reported outcomes to understand the impact of these treatment approaches in everyday practice. Participation involves observation and data collection without altering prescribed therapies, continuing until the study completion in December 2030.